Makhachkala

Researchers are studying uncontrolled asthma in adults across Russia to better understand its characteristics and treatment patterns. This large-scale observational registry will include 9,000 patients from 70 outpatient centers in about 50 regions, focusing on those not receiving biologic therapy. The study aims to describe demographic and clinical features, capture complications and comorbidities, and evaluate routine therapies used in real practice. The study has an ambispective design with two main visits. At the first visit, physicians will collect baseline data from the past 52 weeks using medical records and patient interviews. The second visit, conducted 12 weeks later, will gather follow-up information on treatment changes and clinical outcomes. A subgroup of 500 patients using fixed-dose combination budesonidesalbutamol will have an additional third visit 12 weeks after the second to collect further data. Participants will undergo routine clinical assessments during 2 to 3 visits following standard practice. Researchers will examine demographic and clinical data, blood and sputum eosinophil counts, total IgE levels, asthma control status, lung function tests, exacerbation rates, and healthcare resource use. Safety monitoring aligns with routine care, and the study does not involve any experimental treatments or procedures. Total participation spans approximately 24 weeks for those in the extended follow-up group.

Researchers are conducting a multicenter observational study in Russia to examine treatment methods and the prevalence of HER2-positive status in various stages of bladder cancer, including PD-L1-positive status in metastatic bladder cancer. The study aims to collect and analyze epidemiologic data without changing routine clinical care. Approximately 600 adult patients with urothelial bladder cancer will be enrolled from about 30 specialized oncology centers, divided into three equal groups based on cancer stage high-risk non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. Participants will be observed during a single routine clinical visit where demographic, clinical, and treatment information will be recorded. Tumor tissue samples collected during standard care will be sent to a central laboratory for testing. No interventions or additional diagnostic procedures will be performed as part of the study. Enrollment is expected to continue for about 18 months or until 600 patients have been included and all necessary data and test results are collected. Participants provide their medical data, including treatment history, during their routine visits, and tumor samples are analyzed centrally. Researchers will measure various outcomes related to treatment patterns and biomarker prevalence over a 24-month period. The study focuses on proportions of patients receiving different treatments, relapse rates, progression timelines, and biomarker status. There is no follow-up planned beyond the single visit, and safety monitoring is not part of this observational study.